Revvity, Inc. has lifted its 2025 adjusted earnings‑per‑share outlook to exceed the previously issued range of $4.90 to $5.00, a move announced on January 12, 2026. The company’s updated guidance now projects adjusted EPS that surpasses the upper end of that range, signaling stronger profitability than management had anticipated.
The new guidance follows a prior forecast issued on October 27, 2025, which set the $4.90‑$5.00 band. Analysts had been pricing in a 2025 adjusted EPS of $5.06, and the consensus estimate for the current year was $4.94. By raising its outlook above the $5.00 mark, Revvity is now expected to beat both its own earlier guidance and the consensus estimate, underscoring confidence in its operating performance.
Revvity’s recent quarterly results provide context for the upward revision. In the third quarter of 2024, the company reported an adjusted EPS of $1.18, topping the consensus estimate of $1.14, while the same quarter in 2023 yielded $1.28. Full‑year 2024 GAAP EPS stood at $2.20, with adjusted EPS from continuing operations at $4.90 versus $4.65 in 2023. These figures illustrate a steady improvement in earnings quality and a narrowing of the gap between adjusted and GAAP earnings, which supports the higher 2025 outlook.
Revenue guidance for 2025 has also been raised. Revvity now expects reported revenue growth of approximately 4% and organic growth of about 3% for the full year, up from the prior guidance of 4% reported and 2% organic. Adjusted operating margin is projected to remain around 28.3%, slightly above the 28.0% margin recorded in 2023, reflecting disciplined cost management and a favorable product mix. The company’s life‑sciences and diagnostics segments continue to drive growth, with the life‑sciences arm benefiting from increased demand for reagents and instruments in biopharma and academic research.
CEO Prahlad Singh emphasized that the guidance lift reflects “strong execution and a favorable mix of demand across our core segments.” He noted that the company’s transformation over the past few years has positioned it well for 2025, and that the updated outlook signals confidence in sustaining profitability amid a dynamic macroeconomic backdrop. The guidance revision, combined with the solid quarterly performance, suggests that Revvity’s strategic initiatives—such as expanding its diagnostics portfolio and investing in high‑margin life‑sciences products—are delivering tangible results.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.